Lucid Capital Markets has initiated coverage on Xtant Medical stock, assigning a "Buy" rating and a price target of $1.00. This move signals analyst confidence in the medical device company's future performance.
Lucid Capital Initiates Coverage on Xtant Medical With Buy Rating, $1 Target
XTNTMedical DevicesAnalyst RatingPrice Target
